CAMBRIDGE, Mass., November 19, 2018 — Generation Bio, a company developing the first genetic medicines that can be titrated to effect and re-dosed for a lifetime of benefit, today announced that the company will present at the Evercore ISI Healthcare Conference in Boston, MA. President and Chief Executive Officer Geoff McDonough will provide an overview of the company on Wednesday, November 28, 2018 at 9:50 a.m. EST.
To access a live webcast and subsequent archived recording of the presentation, please visit the “News” section on the Generation Bio website at www.generationbio.com/news/
About Generation Bio
Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people unaffected by inherited disease. The company’s therapies are based on its proprietary ceDNA technology, which delivers durable, high levels of gene expression and can be re-dosed to titrate to effect and to sustain impact over a lifetime. Generation Bio was founded and launched by Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.generationbio.com or follow @generationbio.
Investor contact:
Stern Investor Relations
(212) 362-1200
generationbio@sternir.com
Media contact:
Sarah Sutton
Ten Bridge Communications
(518) 932-3680
sarah@tenbridgecommunications.com
